Experts highlighted research showing that even mild COVID can result in cognitive impairment including brain fog and IQ decline, the FDA approved Pfizer's RSV vaccine for adults aged 18 to 59, E coli outbreak linked to McDonald's Quarter Pounders, and more.

Iterum Therapeutics receives approval for Orlynvah as the first oral penem for treating uncomplicated urinary tract infections in adult women with limited treatment options.

Links to consumed hamburgers have resulted in 75 infections and one fatality, prompting an investigation of the slivered onions used on these beef patties.

Christine Slover, PharmD discussed cefiderocol's effectiveness against challenging infections, including those caused by multi-drug resistant bacteria.

David Richards emphasized the therapy’s potential to enhance antibiotic effectiveness by targeting bacterial biofilms, a significant challenge in treatment.

This new indication for the bivalent respiratory syncytial virus prefusion F vaccine (Abrysvo) makes it the broadest currently available.

Important vaccine updates, including a second COVID-19 vaccine dose for adults 65 and older and immunocompromised individuals, a pneumococcal vaccine for adults aged 50 and older, and more.

Timothy Ritter, MD, provides his insights on using the live biotherapeutic product and what both patients and clinicians can expect in terms of safety and efficacy.

The individuals are agricultural workers in Washington state who were in close proximity to and working with infected poultry at an egg farm.

The late-breaking ID Week session reported on the once-weekly oral regimen being studied for use in people with HIV who are virologically suppressed.

At ID Week 2024, in a late-breaking presentation, investigators are reporting it is safe to cut the antibiotic regimen in half without endangering patients for these infections.

At ID Week 2024, ViiV Healthcare reports its long-acting PrEP, cabotegravir (Apretude), is more than 99% effective.

Catherine Chappell, MD, MSc, presents what we know so far, highlighting the safety and effectiveness of direct-acting antivirals, the importance of shared decision-making, and the need for patient-provider discussions to ensure informed choices about care.

A phase 3 therapy, zoliflodacin, has shown to be noninferior in a late stage trial. The therapy's manufacturer, Innoviva Speciality Therapeutics, is presenting data at this week's ID Week. The company's CMO David Altarac, MD, offers some insights on the therapy and the timeline for filing the paperwork for prospective FDA approval.

A serious adverse event of motor neuropathy reported in September 2024 has resulted in a hold on the investigational new drug application.

At this week’s ID Week, Ferring Pharmaceuticals shares results from its outpatient study examining its treatment, Rebyota, for the prevention of recurrence.

The Hawaii Department of Health released a report detailing the alarming link between hepatitis C and premature mortality in the state.

It is important to recognize this organ that has multiple life-enhancing functions.

The study indicates that targeting the sympathetic nervous system could improve CDI management, as a novel multi-target mRNA vaccine was shown to protect mice from lethal doses.

The state's outbreak has reached over 100 confirmed cases among dairy herds, contributing to a national total of 300 outbreaks across 14 states.

Last year, several cases were identified in American patients traveling to Mexico to receive cosmetic surgery. The source of transmission was discovered, and one of the investigators, Sarah Bergbower DCLS, MS, MLS (ASCP)CM, discusses her part with 1 of the cases.

The Xpert HCV assay facilitates rapid HCV diagnosis in nonclinical settings, aiding high-risk populations like those under community supervision.

This week, recent investigations link contaminated ice machines to Burkholderia multivorans infections, the hepatitis treatment market is projected to grow to USD 30.2 billion by 2032, 2020 guidelines recommend targeting specific AUC levels for optimizing vancomycin therapy, and more

A NIH-funded study focused on analyzing the Wuhan strain in unvaccinated patients with COVID-19. Results showed those with certain blood types seemed to fare worse significantly increasing their risk for cardiovascular events and mortality.

Despite evidence of their effectiveness in reducing hospitalization and mortality rates, many older individuals remain untreated, with recent studies highlighting significant disparities in treatment access and adherence.